The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Richard Ramanius - Redeye AB - Analyst
: Good afternoon. I had some questions about costs and some about your studies. I'll start with the cost questions.
I have two questions which are related. The first one is, what proportion of the start-up costs in relation to total costs do you have in your clinical
studies? That is, how much do you pay at the start and how much during the costs? And related to this, expect costs will have to decrease -- operating
costs will have to decrease in the coming quarters if your cash position is to last into 2025.
Question: Richard Ramanius - Redeye AB - Analyst
: Okay. I understand. It's just you have substantial upfront costs, I think that is correct to say.
Question: Richard Ramanius - Redeye AB - Analyst
: Makes sense. My second question is not really from the cost perspective. But perhaps, you might comment on the cost as well. What trials are still
active and have patients on treatment? And I think I'm starting from CANFOUR and forward, let's say, except for these last two, TRIFOUR and CAN10,
which obviously are recruiting.
Question: Richard Ramanius - Redeye AB - Analyst
: Okay. And then my last question: could -- I guess to your end, could you say any more about the next triggers for CIRIFOUR and CESTAFOUR? When
would we get more information from those studies?
Question: Richard Ramanius - Redeye AB - Analyst
: Okay. Thank you very much. That's all for me.
Question: Sebastiaan van der Schoot - Van Lanschot Kempen NV - Analyst
: Hi, team. Thank you for taking my questions. The first one is on the CAN10 study. I'm wondering whether you will be able to enroll the psoriasis
patients already within 2024. And what will drive the inclusion of patients with sclerosis or myocarditis? And then, I have a follow up question.
Question: Sebastiaan van der Schoot - Van Lanschot Kempen NV - Analyst
: Okay. And what will drive the inclusion of patients with sclerosis or myocarditis? Do we first need to see data on psoriasis patients? Or --
Question: Sebastiaan van der Schoot - Van Lanschot Kempen NV - Analyst
: Okay, got it. And then regarding the PDAC study, the new Phase II randomized, can you maybe expand a little bit on the anticipated recruitment
rate? How many sites will be in enrolling patients? And how does that compare to the CANFOUR study?
Question: Sebastiaan van der Schoot - Van Lanschot Kempen NV - Analyst
: Okay, got it. Thank you.
Question: Sten Westerberg - Analysguiden - Analyst
: Good afternoon, everybody. I wonder if you could expand a little bit on why you decided to move away from an interim analysis in the TRIFOUR
study. Is there any specific reason for this decision?
Question: Sten Westerberg - Analysguiden - Analyst
: Okay, fair enough. Last question then. Is it still your timeline to have a fully recruited study by the end of this -- or by the end of mid next year?
Question: Sten Westerberg - Analysguiden - Analyst
: Yes. Yes, the TRIFOUR.
Question: Sten Westerberg - Analysguiden - Analyst
: Okay, fair enough. Thank you very much. That concludes my questions.
Question: Sebastiaan van der Schoot - Van Lanschot Kempen NV - Analyst
: Hi, guys. I just wanted to follow up on the question with the TRIFOUR and the futility analysis. You just mentioned that it didn't really make sense
to disclose the data. I'm just wondering what the futility was based on. Was it solely based on safety? Or were there also necessary efficacy signal
compared to the control arm necessary?
Question: Sebastiaan van der Schoot - Van Lanschot Kempen NV - Analyst
: Okay, got it.
Question: Sebastiaan van der Schoot - Van Lanschot Kempen NV - Analyst
: Okay, clear. Thank you.
| 
